Y-mAbs Therapeutics YMAB 深 沪
等待开盘 09-26 09:30:00 美东时间
8.61
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.61
- 总市值 3.90亿
- 52周最高 16.11
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.55
- 委 比 0.00%
- 总股本 4529.58万
- 历史最高 55.215
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.70
- 每 手 1
- 风险率 3.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Y-Mabs Therapeutics Completes Merger with Perseus BidCo
Y-Mabs Therapeutics ( ($YMAB) ) has issued an announcement. On September 16, 20...
09-16 21:20
Earnings Scheduled For August 8, 2025
Companies Reporting Before The Bell • BeOne Medicines (NASDAQ:ONC) is expected ...
08-08 16:32
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast
Y-mAbs Therapeutics (NASDAQ:YMAB) is gearing up to announce its quarterly earni...
08-08 00:03
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a biopharmaceutical company focused on antibody-based therapies for cancer, announced it will report second quarter 2025 results before the market open on August 8, 2025. Due to the previously announced transaction with affiliated entities of SERB Pharmaceuticals, the company will not host an earnings conference call. Y-mAbs specializes in novel radioimmunotherapy and antibody-based cancer products, with ...
08-07 11:30
美股牛股 | 创新药企YMAB单日翻倍！华米科技再升38%，近一个月涨幅超770%
创新药企YMAB单日翻倍！获SERB制药宣布全现金收购；华米科技隔夜再升38%，Q2业绩显著提升，近一个月累涨超770%>>
08-06 17:04
Jones Trading Downgrades Y-mAbs Therapeutics to Hold
Jones Trading analyst Justin Walsh downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Buy to Hold.
08-06 05:02
Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals
An announcement from Y-Mabs Therapeutics ( ($YMAB) ) is now available. On Augus...
08-05 21:58
Y-MAbs Therapeutics shares are trading higher after the company announced it will be acquired for approximately $412 million following a merger agreement with Serb Pharmaceuticals.
Y-MAbs Therapeutics shares are trading higher after the company announced it wi...
08-05 21:11
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
SERB Pharmaceuticals has agreed to acquire Y-mAbs Therapeutics in an all-cash transaction valued at approximately $412 million, including its key oncology product DANYELZA® (naxitamab-gqgk). Y-mAbs stockholders will receive $8.60 per share, a 105% premium to the closing price on August 4, 2025. DANYELZA, the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma, will expand SERB's rare oncology portfolio, complementing p...
08-05 12:30
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
